The company highlighted strong progress in 2025, including a significant increase in LOQTORZI sales and a major reduction in debt levels, with management emphasizing its transition toward an oncology-focused business, supported by growing revenues, potential partnership opportunities, and a pipeline with multiple clinical catalysts expected in 2026. Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers.
Cyborg Score Rationale
The company demonstrates strong product momentum with LOQTORZI sales doubling in 2025 and substantial debt reduction (90% reduction since 2024 peak). However, the Altman Z-Score of -2.02 places the company in the distress zone, indicating a potential risk of bankruptcy, and profitability remains challenged. High volatility and early-stage clinical assets present execution risk.
Top Insights
Company doubled LOQTORZI sales while completing transformation from biosimilars to innovative oncology company focused on overcoming immune resistance in cancer
Reduced overall debt since peak in 2024 by over 90% to $38.8 million
Pipeline includes LOQTORZI (toripalimab-tpzi) treating Nasopharyngeal Carcinoma, Casdozokitug for Hepatocellular Carcinoma and NSCLC, and CHS-114/CHS-1000 targeting solid tumors
2025 revenue of $42.2M with 59.8% growth versus 2024, though with 147 employees and market cap of $227.8M
Named Competitors
Keytruda — Leading PD-1 checkpoint inhibitor for multiple cancer types
Opdivo — Anti-PD-1 immunotherapy for various solid tumors
Tecentriq — PD-L1 inhibitor for multiple oncology indications
Libtayo — PD-1 inhibitor for non-small cell lung cancer and other malignancies
Recent Developments
(March 2026) Q4 2025 earnings: EPS (34c) vs consensus (31c), revenue $12.8M vs $14.1M expected
(February 2026) Public stock offering announcement with market cap ~$242.95M
(May 2025) Official name change from Coherus BioSciences to Coherus Oncology, Inc.
Open the full interactive Coherus Oncology, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.